Elinzanetant (BAY3427080)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Vasomotor Symptoms Associated With Menopause

Clinical Trial

Last updated: 12/13/2025

Regulatory Approvals

EMA11/17/2025

Lynkuet

Treatment of moderate to severe vasomotor symptoms (VMS).

Developer

BAYRY

BAYER

Related Pipeline

Colorectal Neoplasms

Pneumonia, Bacterial

Overactive Bladder

Chronic Kidney Disease

Oral Contraceptive